Targeted agents and immunotherapies: optimizing outcomes in melanoma
Targeted agents and immunotherapies: optimizing outcomes in melanoma
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Key Points
Clinical therapeutics for advanced-stage melanoma have improved dramatically with the development of BRAF and MEK inhibitors, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell-death protein 1 (PD-1) blocking antibodies, and a modified oncolytic herpes virus that is delivered intratumourally
The overall surviv...
Alternative Titles
Full title
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1884166752
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1884166752
Other Identifiers
ISSN
1759-4774
E-ISSN
1759-4782
DOI
10.1038/nrclinonc.2017.43
